Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 2Anemia 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Fatigue 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 16Nivolumab 9atezolizumab 7Docetaxel 7Cyclophosphamide 5durvalumab 4Ipilimumab 4Gemcitabine 4avelumab 3Specimen Handling 3Radiotherapy 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3temsirolimus 2spartalizumab 2sargramostim 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2aldesleukin 2abiraterone 2Therapeutics 2Standard of Care 2Radiosurgery 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Epoetin Alfa × Genitourinary × Clear all
NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
201 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡